ArticleDiagnostics (Basel, Switzerland)2022
Rapid SARS-CoV-2 Detection Using the Lucira™ Check It COVID-19 Test Kit.
Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The Use of CRISPR-Cas Systems for Viral Detection: A Bibliometric Analysis and Systematic Review.Biosensors · 2025Pooled it
- Point of Care Testing and Recombinase Polymerase Amplification.Journal of clinical laboratory analysis · 2026Article
- Heat-actuated valve implementation in a point-of-care, paper-based microfluidic device for infectious disease detection.PloS one · 2026Article
- Isothermal nucleic acid amplification for monitoring hand-foot-and-mouth disease: current status and future implications.Mikrochimica acta · 2024Review
- Sample preparation and detection methods in point-of-care devices towards future at-home testing.Lab on a chip · 2024Review
- Post-market surveillance of six COVID-19 point-of-care tests using pre-Omicron and Omicron SARS-CoV-2 variants.Microbiology spectrum · 2024Article
- At-home testing for respiratory viruses: a minireview of the current landscape.Journal of clinical microbiology · 2024Review
- Rapid Nucleic Acid Diagnostic Technology for Pandemic Diseases.Molecules (Basel, Switzerland) · 2024Review
- A decade of clinical microbiology: top 10 advances in 10 years: what every infection preventionist and antimicrobial steward should know.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Review
- Clinical validation of RCSMS: A rapid and sensitive CRISPR-Cas12a test for the molecular detection of SARS-CoV-2 from saliva.PloS one · 2024Article
- Self-tests for COVID-19: What is the evidence? A living systematic review and meta-analysis (2020-2023).PLOS global public health · 2024Article
- Point-of-Care Devices for Viral Detection: COVID-19 Pandemic and Beyond.Micromachines · 2023Review
- Mayaro virus detection by integrating sample preparation with isothermal amplification in portable devices.Analytical and bioanalytical chemistry · 2023Article
- Multicenter evaluation of a simple and sensitive nucleic acid self-testing for SARS-CoV-2.Virologica Sinica · 2023Article
- Engineering Innovative Interfaces for Point-of-Care Diagnostics.Current opinion in colloid & interface science · 2023Review
- Prospective Performance Evaluation of the miDiagnostics COVID-19 PCR Test for Rapid SARS-CoV-2 Detection on Nasopharyngeal Swabs.Journal of clinical microbiology · 2023Article
- Rapid and Sensitive Diagnosis of COVID-19 Using an Electricity-Free Self-Testing System.Biosensors · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The need for the early identification of SARS-CoV-2 has let to a quest for reliable tests that meet the standards of polymerase chain reaction (PCR) tests, on the one hand, and are low-cost, easy-to-use, and fast, on the other hand. One such test is the Lucira™ Check It COVID-19 Test kit (“Lucira”) (Lucira Health, Inc., Emeryville, CA, USA), which utilizes real-time loop-mediated isothermal amplification technology, developed for at-home use. This study evaluated the clinical sensitivity and specificity of Lucira in identifying the virus in 190 nasopharyngeal samples collected between January and October 2021. Each sample was also subjected to RT-PCR. All negative RT-PCR results were paralleled by a negative Lucira result. Out of 90 participants who had a positive RT-PCR result, 82 (91.1%) tested positive by Lucira. Among the 72 symptomatic participants, 67 (93%) tested positive by Lucira. All samples with a positive RT-PCR result with a threshold cycle (Ct) > 36, yielded a negative Lucira result. In addition, a significant positive correlation was found between Ct and time-to-positivity with Lucira (R = 0.8612, p < 0.0001). The implementation of such a portable and affordable assay may aid in breaking the COVID-19 transmission chain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.